N/A
Completed N=88
Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant
Etonogestrel Contraceptive Implant, Bothersome Bleeding
Source: ClinicalTrials.gov NCT02353247 ↗
Enrolled (actual)
88
Serious AEs
0.0%
Results posted
Mar 2022
Primary outcomePrimary: Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant — 2.73; 2.77; 2.76; 2.27 units on a scale
Summary
The overall objective of this study is to confirm that oral progesterone is an effective way to manage bothersome bleeding; thus increasing the rate of continuation of the etonogestrel contraceptive implant in adolescents.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Impact of Aygestin (and Dose of Aygestin) on the Management of Bothersome Bleeding Associated With the Etonogestrel Contraceptive Implant |
2.73; 2.77; 2.76; 2.27; 2.65; 2.67 | — |
Eligibility Criteria
Inclusion Criteria
- Inclusion criteria will include any post---menarchal female presenting to the Kosair Children's Hospital Gynecologic Specialist practice, who desires to use the etonogestrel contraceptive implant and has access to a mobile phone device.
Exclusion Criteria
- NA
Data sourced from ClinicalTrials.gov (NCT02353247). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.